The FDA alerted the public that preliminary results from a safety clinical trial found an increased risk of serious heart related problems and cancer with Xeljanz (tofacitinib) and Xeljanz XR. These drugs are indicated for the treatment of rheumatoid arthritis, which may develop in workers’ comp populations due to cumulative or acute trauma, or when a pre-existing inflammatory joint disease is made worse by an occupational injury.
